Company intelligence / Profile preview

CBRA

Aurora, Colorado, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Cerebral Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for refractory neurological diseases. The company utilizes a proprietary implanted infusion system to deliver medications directly into the fluid-filled ventricles of the brain, bypassing the blood-brain barrier. This targeted delivery approach aims to increase efficacy while minimizing systemic side effects. Their lead program, CT-010, is a proprietary formulation of valproate sodium currently being evaluated for the treatment of medically refractory epilepsy.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

Photocil

Unknown

Partnerships

Medtronic

Beyond the preview

Go deeper on CBRA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBRA.

Explore the full profile